Abbott Laboratories: PharmaVitae Profile

Content

• CHAPTER 1 ABOUT THIS PROFILE
  • Executive summary
  • Quarterly news update
  • Company introduction
  • Company sales
  • Company financials
  • Key products and competitors
  • Data sourcing
  • Sales data
  • Analyst consensus
• CHAPTER 2 EXECUTIVE SUMMARY
  • Key findings
  • Prescription pharmaceutical sales performance, 200113
  • Financial performance, 200113
  • Abbott: PharmaVitae forecasts at a glance
  • Strategic insight
  • SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats
• CHAPTER 3 QUARTERLY NEWS UPDATE
  • Product developments
  • Deals and alliances
  • Product deals
  • Technology deals
  • M&A activity
  • Company announcements
  • Future product milestones
• CHAPTER 4 COMPANY INTRODUCTION
  • Key findings
  • Background
  • Key corporate developments
  • M&A history
  • Knoll Pharmaceuticals
  • Kos Pharmaceuticals
  • M&A strategy
  • Current corporate structure
  • Pharmaceuticals
  • Nutritionals
  • Diagnostics
  • Vascular
  • Pharmaceuticals business unit structure
• CHAPTER 5 COMPANY SALES
  • Key findings
  • Prescription pharmaceutical sales and growth rate analysis, 200113
  • Historical analysis
  • Forecast analysis
  • Product analysis
  • Product analysis, 200107
  • Product analysis, 200713
  • Therapy area analysis
  • Therapy area analysis, 200107
  • Therapy area analysis, 200713
  • Therapy area focus, 200113
  • Geographic analysis
  • Geographic analysis, 200107
  • Geographic analysis, 200713
  • Geographic focus, 200113
  • Launch/core/expiry analysis
  • Explanation of launch/core/expiry analysis
  • Launch analysis, 200713
  • Core analysis, 200713
  • Expiry analysis, 200713
  • Launch/core/expiry configuration, 200713
  • Molecule type analysis
  • Molecule type analysis, 200107
  • Molecule type analysis, 200713
  • Externalization analysis
  • Externalization analysis, 200107
  • Externalization analysis, 200713
• CHAPTER 6 COMPANY FINANCIALS
  • Key findings
  • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 200107
  • Financial statements, 200107
  • Profit and loss account, 200107
  • Balance sheet, 200107
  • Operating costs and profit analysis
  • Operating costs and profit analysis, 200107
  • Operating cost ratio and profit margin analysis, 200107
  • Operating cost ratio and profit margin analysis, 200713
  • Operating costs and profit analysis, 200713
  • Return on capital employed analysis
  • Capital employed analysis, 200107
  • Return on capital employed (RoCE) analysis, 200107
  • Market capitalization analysis
  • Market capitalization analysis, 200107
  • Total shareholder returns analysis, 200107
• CHAPTER 7 KEY PRODUCTS AND COMPETITORS
  • Key findings
  • Overview
  • Immunology & inflammation
  • Humira
  • Cardiovascular
  • Fenofibrate franchise (TriCor/TriLipix/TriLipix&Crestor)
  • Simcor/Niaspan
  • Infectious diseases
  • Kaletra
  • Respiratory
  • Flutiform
  • Oncology
  • Lupron
  • Central nervous system
  • Depakote
• CHAPTER 8 APPENDIX
  • R&D pipeline
  • References
  • Abbreviations
  • Exchange rates
• TABLE OF TABLES
  • Table 1: Abbott PharmaVitae forecasts at a glance
  • Table 2: Overview of Abbotts lipid management portfolio
  • Table 3: Abbott key product developments, Q1 2008
  • Table 4: Abbott product deals and alliances, Q1 2008
  • Table 5: Abbott technology deals and alliances, Q1 2008
  • Table 6: Abbott M&A activity, Q1 2008
  • Table 7: Abbott company announcements, Q1 2008
  • Table 8: Abbott future product milestones, 200810
  • Table 9: Abbott product portfolio overview ($m), 200107
  • Table 10: Abbott product portfolio overview ($m), 200713
  • Table 11: Abbott product portfolio overview ($m), 200107
  • Table 12: Abbott product portfolio overview ($m), 200713
  • Table 13: Abbott portfolio overview by geographic region ($m), 200107
  • Table 14: Abbott portfolio overview by geographic region ($m), 200713
  • Table 15: Abbott launch portfolio overview ($m), 200713
  • Table 16: Abbott core portfolio overview ($m), 200713
  • Table 17: Abbott expiry portfolio overview ($m), 200713
  • Table 18: Abbott portfolio overview by molecule type ($m), 200107
  • Table 19: Abbott product portfolio overview by molecule type ($m), 200713
  • Table 20: Abbott product portfolio overview by source ($m), 200107
  • Table 21: Abbott product portfolio overview by source ($m), 200713
  • Table 22: Total Abbott sales by business unit ($m), 200107
  • Table 23: Abbott profit and loss account ($m), 200107
  • Table 24: Abbott balance sheet ($m), 200107
  • Table 25: Abbott operating revenue/cost analysis ($m), 200107
  • Table 26: Abbott operating cost ratio analysis (% of total revenues), 200107
  • Table 27: Abbott operating cost ratio analysis (% of total revenues), 200713
  • Table 28: Abbott operating revenue/cost analysis ($m), 200713
  • Table 29: Abbott capital employed ($m), 200107
  • Table 30: Abbott EBIT return on capital employed ($m), 2001-07
  • Table 31: Abbott EBIT pre-tax return/Capital employed driver analysis (%), 200107
  • Table 32: Abbott market capitalization ($ billion), 200107
  • Table 33: Abbott total shareholder returns (annual %), 200107
  • Table 34: Key products overview
  • Table 35: Humira: overview
  • Table 36: Humira: sales forecast ($m), 200713
  • Table 37: Overview of anti-TNF market
  • Table 38: TriCor: overview
  • Table 39: TriLipix: overview
  • Table 40: TriLipix/Crestor: overview
  • Table 41: TriCor: sales forecast ($m), 200713
  • Table 42: TriLipix: sales forecast ($m), 200713
  • Table 43: TriLipix/Crestor: sales forecast ($m), 200713
  • Table 44: Major dyslipidemia therapeutics, global sales ($m), 200107
  • Table 45: Simcor: overview
  • Table 46: Niaspan: overview
  • Table 47: Simcor: sales forecast ($m), 200713
  • Table 48: Niaspan: sales forecast ($m), 200713
  • Table 49: Kaletra: overview
  • Table 50: Kaletra: sales forecast ($m), 200713
  • Table 51: Top five anti-HIV treatments, global sales ($m), 2001 & 2007
  • Table 52: Flutiform: overview
  • Table 53: Flutiform: sales forecast ($m), 200713
  • Table 54: Lupron: overview
  • Table 55: Lupron: sales forecast ($m), 200713
  • Table 56: Depakote: overview
  • Table 57: Depakote: sales forecast ($m), 200713
  • Table 58: Top anti-epileptic therapeutics, sales ($m) 200107
  • Table 59: Abbotts R&D pipeline (Phase Iregistration)
  • Table 60: Exchange rates, 2007
• TABLE OF FIGURES
  • Figure1: Abbott prescription pharmaceutical performance, sales ($m) and growth rate (%), 200113
  • Figure2: Abbotts financial performance ($m), 200113
  • Figure3: Sales contribution from M&A activity ($m), 200713
  • Figure4: Sales of Abbotts lipid management portfolio ($m), 200713
  • Figure5: Abbott SWOT analysis
  • Figure6: Current corporate structure
  • Figure7: Pharmaceuticals business unit structure
  • Figure8: Abbott prescription pharmaceutical performance, sales ($m) and growth rate (%), 200113
  • Figure9: Abbott key sales growth driver & resistors ($m), 200107
  • Figure10: Abbott key sales growth drivers & resistors ($m), 200713
  • Figure11: Abbott prescription pharmaceutical sales by therapy area ($m), 200113
  • Figure12: Abbott prescription pharma sales by therapy area (% of total), 200113
  • Figure13: Abbott prescription pharmaceutical sales by geographic region ($m), 200113
  • Figure14: Abbott growth drivers and resistors by geographic region ($m), 200107
  • Figure15: Abbott drivers and resistors by geographic region ($m), 200713
  • Figure16: Abbott prescription pharmaceutical sales by geographic region (% of total), 200113
  • Figure17: Abbott launch/core/expiry configuration ($m), 200713
  • Figure18: Abbott prescription pharmaceutical sales by molecule type ($m), 200113
  • Figure19: Abbott growth drivers and resistors by molecule type ($m), 200713
  • Figure20: Abbott prescription pharmaceutical sales by source ($m), 200113
  • Figure21: Abbott growth drivers and resistors by source ($m), 200713
  • Figure22: Abbott operating revenue/cost analysis ($m), 200113
  • Figure23: Abbott operating cost ratio analysis (% of total revenues), 200113
  • Figure24: Abbott return on capital employed, EBIT margin and capital turnover, 200107
  • Figure25: Return on capital employed formula
  • Figure26: Abbott market capitalization ($ billion), 200107
  • Figure27: Abbott total shareholder returns vs. S&P 500 ($m), 200107